Cancer Immunotherapy Using Chimeric Antigen Receptor Expressing T-Cells: Present and Future Needs of Clinical Cancer Centers
Chimeric Antigen Receptor-T cells (CAR-T) are considered novel biological agents, designed to selectively attack cancer cells expressing specific antigens, with demonstrated clinical activity in patients affected with relapsed/refractory B-cell malignancies. In consideration of their complexity, the...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2020-10-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2020.565236/full |
| _version_ | 1818244172608438272 |
|---|---|
| author | Manuel Gotti Irene Defrancesco Mario D’Angelo Sabrina Basso Sabrina Basso Luca Crotto Alfredo Marinelli Alfredo Marinelli Cristina Maccalli Vincenzo Iaconianni |
| author_facet | Manuel Gotti Irene Defrancesco Mario D’Angelo Sabrina Basso Sabrina Basso Luca Crotto Alfredo Marinelli Alfredo Marinelli Cristina Maccalli Vincenzo Iaconianni |
| author_sort | Manuel Gotti |
| collection | DOAJ |
| description | Chimeric Antigen Receptor-T cells (CAR-T) are considered novel biological agents, designed to selectively attack cancer cells expressing specific antigens, with demonstrated clinical activity in patients affected with relapsed/refractory B-cell malignancies. In consideration of their complexity, the use of CAR-T requires dedicated clinical setting and health care practitioners with expertise in the selection, treatment, and management of toxicities and side effects. Such issue appears particularly important when contextualized in the rapid progress of CAR-T cell treatment, translating into a constant need of updating and evolution. Moreover, the clinical grade manufacturing of CAR-T cells is complex and implies articulated regulatory and organizational aspects. The main goal of this review is to summarize and provide an accurate analysis of the clinical, logistic, and regulatory requirements of CAR-T cell centers. Finally, we describe a new occupational figure called “CAR-T specialist” devoted to the establishment and coordination of the required facilities and regulatory landscape in the context of cancer centers. |
| first_indexed | 2024-12-12T14:12:48Z |
| format | Article |
| id | doaj.art-2831880b954647fba1bebfca36b583de |
| institution | Directory Open Access Journal |
| issn | 1664-3224 |
| language | English |
| last_indexed | 2024-12-12T14:12:48Z |
| publishDate | 2020-10-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj.art-2831880b954647fba1bebfca36b583de2022-12-22T00:21:59ZengFrontiers Media S.A.Frontiers in Immunology1664-32242020-10-011110.3389/fimmu.2020.565236565236Cancer Immunotherapy Using Chimeric Antigen Receptor Expressing T-Cells: Present and Future Needs of Clinical Cancer CentersManuel Gotti0Irene Defrancesco1Mario D’Angelo2Sabrina Basso3Sabrina Basso4Luca Crotto5Alfredo Marinelli6Alfredo Marinelli7Cristina Maccalli8Vincenzo Iaconianni9Division of Hematology, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Policlinico San Matteo, Pavia, ItalyDepartment of Molecular Medicine, University of Pavia, Pavia, ItalyDepartment of Onco-hematology, Cell and Gene Therapy, Ospedale Pediatrico Bambino Gesù IRCCS, Roma, ItalyPediatric Hematology/Oncology Unit, Fondazione IRCCS Policlinico San Matteo, Pavia, ItalyCell Factory, Fondazione IRCCS Policlinico San Matteo, Pavia, ItalyCandiolo Cancer Institute, FPO–IRCCS, Candiolo, ItalyOperative Unit (OU) Neuroncology, University Federico II, Napoli, ItalyIRCCS Neuromed Istituto Neurologico Mediterraneo Pozzilli (INM), Pozzilli, ItalyLaboratory of Immune and Biological Therapy, Research Department, Sidra Medicine, Doha, Qatar0ICMED, Sesto San Giovanni, ItalyChimeric Antigen Receptor-T cells (CAR-T) are considered novel biological agents, designed to selectively attack cancer cells expressing specific antigens, with demonstrated clinical activity in patients affected with relapsed/refractory B-cell malignancies. In consideration of their complexity, the use of CAR-T requires dedicated clinical setting and health care practitioners with expertise in the selection, treatment, and management of toxicities and side effects. Such issue appears particularly important when contextualized in the rapid progress of CAR-T cell treatment, translating into a constant need of updating and evolution. Moreover, the clinical grade manufacturing of CAR-T cells is complex and implies articulated regulatory and organizational aspects. The main goal of this review is to summarize and provide an accurate analysis of the clinical, logistic, and regulatory requirements of CAR-T cell centers. Finally, we describe a new occupational figure called “CAR-T specialist” devoted to the establishment and coordination of the required facilities and regulatory landscape in the context of cancer centers.https://www.frontiersin.org/articles/10.3389/fimmu.2020.565236/fullCAR-T cellsCAR-T processCAR-T UnitCAR-T SpecialistJACIEGMP |
| spellingShingle | Manuel Gotti Irene Defrancesco Mario D’Angelo Sabrina Basso Sabrina Basso Luca Crotto Alfredo Marinelli Alfredo Marinelli Cristina Maccalli Vincenzo Iaconianni Cancer Immunotherapy Using Chimeric Antigen Receptor Expressing T-Cells: Present and Future Needs of Clinical Cancer Centers Frontiers in Immunology CAR-T cells CAR-T process CAR-T Unit CAR-T Specialist JACIE GMP |
| title | Cancer Immunotherapy Using Chimeric Antigen Receptor Expressing T-Cells: Present and Future Needs of Clinical Cancer Centers |
| title_full | Cancer Immunotherapy Using Chimeric Antigen Receptor Expressing T-Cells: Present and Future Needs of Clinical Cancer Centers |
| title_fullStr | Cancer Immunotherapy Using Chimeric Antigen Receptor Expressing T-Cells: Present and Future Needs of Clinical Cancer Centers |
| title_full_unstemmed | Cancer Immunotherapy Using Chimeric Antigen Receptor Expressing T-Cells: Present and Future Needs of Clinical Cancer Centers |
| title_short | Cancer Immunotherapy Using Chimeric Antigen Receptor Expressing T-Cells: Present and Future Needs of Clinical Cancer Centers |
| title_sort | cancer immunotherapy using chimeric antigen receptor expressing t cells present and future needs of clinical cancer centers |
| topic | CAR-T cells CAR-T process CAR-T Unit CAR-T Specialist JACIE GMP |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2020.565236/full |
| work_keys_str_mv | AT manuelgotti cancerimmunotherapyusingchimericantigenreceptorexpressingtcellspresentandfutureneedsofclinicalcancercenters AT irenedefrancesco cancerimmunotherapyusingchimericantigenreceptorexpressingtcellspresentandfutureneedsofclinicalcancercenters AT mariodangelo cancerimmunotherapyusingchimericantigenreceptorexpressingtcellspresentandfutureneedsofclinicalcancercenters AT sabrinabasso cancerimmunotherapyusingchimericantigenreceptorexpressingtcellspresentandfutureneedsofclinicalcancercenters AT sabrinabasso cancerimmunotherapyusingchimericantigenreceptorexpressingtcellspresentandfutureneedsofclinicalcancercenters AT lucacrotto cancerimmunotherapyusingchimericantigenreceptorexpressingtcellspresentandfutureneedsofclinicalcancercenters AT alfredomarinelli cancerimmunotherapyusingchimericantigenreceptorexpressingtcellspresentandfutureneedsofclinicalcancercenters AT alfredomarinelli cancerimmunotherapyusingchimericantigenreceptorexpressingtcellspresentandfutureneedsofclinicalcancercenters AT cristinamaccalli cancerimmunotherapyusingchimericantigenreceptorexpressingtcellspresentandfutureneedsofclinicalcancercenters AT vincenzoiaconianni cancerimmunotherapyusingchimericantigenreceptorexpressingtcellspresentandfutureneedsofclinicalcancercenters |